SCHEMBL21753705

SCHEMBL21753705

Cc1ccc2nc(NC(=O)c3ccc(N4CCOCC4)cc3)sc2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 10/20 1.00
ALDH1A1 P00352 3/20 0.69
SMN1; SMN2 Q16637 3/20 0.64
HTT P42858 1/20 0.64
MAP3K5 Q99683 1/20 0.64
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
KDM4E B2RXH2 2/20 0.61
HPGD P15428 2/20 0.61
SCD O00767 1/20 0.61
DUSP3 P51452 1/20 0.59
PTPN5 P54829 1/20 0.59
KMT2A Q03164 1/20 0.59
PTPN11 Q06124 1/20 0.59
KLK7 P49862 1/20 0.58
TDP1 Q9NUW8 1/20 0.58
TP53 P04637 1/20 0.58
PKM P14618 1/20 0.58
MAPK1 P28482 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21753710 0.87 LRRK2 (1.00) LRRK2NPC1RAB9ASCDKMT2A
SCHEMBL21753698 0.87 LRRK2 (1.00) LRRK2RAB9ASCDKMT2A
SCHEMBL21753719 0.87 LRRK2 (1.00) LRRK2ALDH1A1HTTNPC1RAB9A
SCHEMBL21753706 0.87 LRRK2 (1.00) LRRK2ALDH1A1HTTNPC1RAB9A
SCHEMBL21753709 0.87 LRRK2 (1.00) LRRK2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL21753690 0.85 LRRK2 (1.00) LRRK2NPC1RAB9ASCD
SCHEMBL21753695 0.84 LRRK2 (1.00) LRRK2ALDH1A1SMN1; SMN2HTTNPC1
SCHEMBL21753691 0.84 LRRK2 (1.00) LRRK2ALDH1A1SMN1; SMN2NPC1RAB9A
SCHEMBL13329390 0.84 MAP3K5 (0.83) LRRK2ALDH1A1SMN1; SMN2HTTMAP3K5
SCHEMBL21753712 0.83 LRRK2 (1.00) LRRK2ALDH1A1SMN1; SMN2KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3827665-B1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR INVESTIGACION (ES) 2025-02-19 EP claimed
US-11912678-B2 LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2024-02-27 US claimed
US-20230025843-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2023-01-26 US claimed
EP-3842422-B1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2022-09-07 EP claimed
US-20210323936-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2021-10-21 US claimed
EP-3842422-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES Consejo Superior de Investigaciones Cientificas (ES) 2021-06-30 EP claimed
WO-2021105182-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2021-06-03 WO claimed
EP-3827665-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-06-02 EP claimed
WO-2020039110-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2020-02-27 WO claimed
EP-3827665-B1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR INVESTIGACION (ES) 2025-02-19 EP disclosed
US-11912678-B2 LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2024-02-27 US disclosed
US-20230025843-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2023-01-26 US disclosed
EP-3842422-B1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR INVESTIGACION (ES) 2022-09-07 EP disclosed
US-20210323936-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2021-10-21 US disclosed
EP-3842422-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES Consejo Superior de Investigaciones Cientificas (ES) 2021-06-30 EP disclosed
WO-2021105182-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC) (ES) 2021-06-03 WO disclosed
EP-3827665-A1 MAMMAL KINASE INHIBITORS TO PROMOTE IN VITRO EMBRYOGENESIS INDUCTION OF PLANTS Consejo Superior de Investigaciones Científicas (CSIC) (ES) 2021-06-02 EP disclosed
WO-2020039110-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (ES) 2020-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210323936-A1 LRRK2 INHIBITING COMPOUNDS AND USE THEREOF FOR TREATING NEURODEGENERATIVE DISEASES LRRK2, PARK7, SNCA LRRK2 1/4885ALDH1A1 971/4885SMN1; SMN2 293/4885
US-11912678-B2 LRRK2 inhibiting compounds and use thereof for treating neurodegenerative diseases LRRK2, PARK7, SNCA LRRK2 1/4885ALDH1A1 971/4885SMN1; SMN2 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.